Literature DB >> 7543211

Influence of CD14, LBP and BPI in the monocyte response to LPS of different polysaccharide chain length.

T G Jahr1, A Sundan, H S Lichenstein, T Espevik.   

Abstract

In this study we examined the involvement of human serum, recombinant lipopolysaccharide binding protein (rLBP), recombinant (r)CD14, CD14 antibodies and recombinant bactericidal permeability-increasing factor (rBPI) in the induction of TNF by Salmonella minnesota LPS of different polysaccharide chain lengths. Soluble rCD14 and rLBP markedly enhanced LPS 6261 TNF production and to a lesser degree also enhanced TNF production from Re 595 LPS and lipid A DP. Addition of anti-CD14 antibodies resulted in nearly complete inhibition of LPS 6261-induced TNF production and partial inhibition of Re 595 LPS and lipid A DP-induced TNF release. The ability of lipid A MP to induce TNF production increased with addition of rCD14. Addition of rLBP or anti-CD14 antibodies had no detectable effect on lipid A MP-induced TNF production. The effect of rBPI was also tested and the results showed that only the TNF-inducing ability from smooth LPS was completely inhibited by rBPI. Recombinant BPI was considerably less effective in inhibiting Re 595 LPS-induced TNF production, and lipid A DP was not affected by rBPI. Our data suggest that the ability of rLBP, rCD14, CD14 antibodies and rBPI to modulate LPS induced TNF production is strongly dependent on the LPS polysaccharide chain length.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543211     DOI: 10.1111/j.1365-3083.1995.tb03634.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  The internalization time course of a given lipopolysaccharide chemotype does not correspond to its activation kinetics in monocytes.

Authors:  A Lentschat; V T El-Samalouti; J Schletter; S Kusumoto; L Brade; E T Rietschel; J Gerdes; M Ernst; H Flad; A J Ulmer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Serum factors, cell membrane CD14, and beta2 integrins are not required for activation of bovine macrophages by lipopolysaccharide.

Authors:  T W Jungi; H Sager; H Adler; M Brcic; H Pfister
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

3.  Role of plasma, lipopolysaccharide-binding protein, and CD14 in response of mouse peritoneal exudate macrophages to endotoxin.

Authors:  D Heumann; Y Adachi; D Le Roy; N Ohno; T Yadomae; M P Glauser; T Calandra
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

4.  Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide-binding protein, CD14, and bactericidal/permeability-increasing factor.

Authors:  T G Jahr; L Ryan; A Sundan; H S Lichenstein; G Skjåk-Braek; T Espevik
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

5.  Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers.

Authors:  T H Flo; L Ryan; L Kilaas; G Skjâk-Braek; R R Ingalls; A Sundan; D T Golenbock; T Espevik
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

6.  Soluble CD14 mediates lipopolysaccharide-induced intercellular adhesion molecule 1 expression in cultured human gingival fibroblasts.

Authors:  J Hayashi; T Masaka; I Saito; I Ishikawa
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

7.  Monophosphoryl lipid A-induced pro-inflammatory cytokine expression does not require CD14 in primary human dendritic cells.

Authors:  Sonja T H M Kolanowski; Suzanne N Lissenberg-Thunnissen; Diba Emal; S Marieke van Ham; Anja Ten Brinke
Journal:  Inflamm Res       Date:  2016-03-18       Impact factor: 4.575

8.  The tumor necrosis factor-inducing potency of lipopolysaccharide and uronic acid polymers is increased when they are covalently linked to particles.

Authors:  G Berntzen; T H Flo; A Medvedev; L Kilaas; G Skjåk-Braek; A Sundan; T Espevik
Journal:  Clin Diagn Lab Immunol       Date:  1998-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.